Phenotypes associated with this allele

• Allele Symbol: Tg(MMTV-ERBB2)5Erick
• Allele Name: transgene insertion 5, Sharon Erickson
• Allele ID: MGI:5527316
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
tg1	Tg(MMTV-ERBB2)5Erick/?	FVB/N-Tg(MMTV-ERBB2)5Erick	MGI:5527317

Genotype
MGI:5527317

tg1

• Allelic Composition: Tg(MMTV-ERBB2)5Erick/?
• Genetic Background: FVB/N-Tg(MMTV-ERBB2)5Erick

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary gland tumor incidence ( J:90202 )

♀ • 76% of females develop asynchronous mammary tumors with an average latency of 28.2 weeks, with the earliest onset at 23 weeks of age

♀ • females treated with an anti-ERBB2 antibody, mu4D5, show reduced mammary tumor incidence and inhibition of tumor growth

increased mammary adenocarcinoma incidence ( J:90202 )

♀ • tumors exhibit features of rapidly growing adenocarcinoma with areas of solid, tubular, and papillary growth, cellular pleomorphism, and mitotic activity

increased Harderian gland adenoma incidence ( J:90202 )

♀ • the enlarged Harderian glands show residual normal-appearing acinar tissue adjacent to circumscribed areas of adenomatous growth, with these areas showing effacement of the normal glandular architecture with solid and papillary growth and showing resemblance to Harderian gland adenoma, acinar type

♀ • Hardarian gland neoplasms are not seen in females treated early with an anti-ERBB2 antibody, mu4D5

increased metastatic potential ( J:90202 )

♀ • pulmonary metastases are seen

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:90202 )

♀ • 76% of females develop asynchronous mammary tumors with an average latency of 28.2 weeks, with the earliest onset at 23 weeks of age

♀ • females treated with an anti-ERBB2 antibody, mu4D5, show reduced mammary tumor incidence and inhibition of tumor growth

increased mammary adenocarcinoma incidence ( J:90202 )

♀ • tumors exhibit features of rapidly growing adenocarcinoma with areas of solid, tubular, and papillary growth, cellular pleomorphism, and mitotic activity

enlarged Harderian gland ( J:90202 )

♀ • enlarged Harderian gland, especially in aging mice that have yet to develop mammary tumors

increased Harderian gland adenoma incidence ( J:90202 )

♀ • the enlarged Harderian glands show residual normal-appearing acinar tissue adjacent to circumscribed areas of adenomatous growth, with these areas showing effacement of the normal glandular architecture with solid and papillary growth and showing resemblance to Harderian gland adenoma, acinar type

♀ • Hardarian gland neoplasms are not seen in females treated early with an anti-ERBB2 antibody, mu4D5

vision/eye

exophthalmos ( J:90202 )

♀ • progressive exopthalamus due to Harderian gland neoplasms

integument

increased mammary gland tumor incidence ( J:90202 )

♀ • 76% of females develop asynchronous mammary tumors with an average latency of 28.2 weeks, with the earliest onset at 23 weeks of age

♀ • females treated with an anti-ERBB2 antibody, mu4D5, show reduced mammary tumor incidence and inhibition of tumor growth

increased mammary adenocarcinoma incidence ( J:90202 )

♀ • tumors exhibit features of rapidly growing adenocarcinoma with areas of solid, tubular, and papillary growth, cellular pleomorphism, and mitotic activity

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:90202